Notify me when MPM BioImpact LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 38 | $873,953,483 | +$350,522,937 | -$241,719,221 | +$108,803,716 | CGEM, MDGL, LQDA, TRVI, EWTX | 13F-HR | 17 Feb 2026, 16:30 |
| Q3 2025 | 40 | $610,879,430 | +$60,680,672 | -$109,010,583 | -$48,329,911 | MDGL, CGEM, RNA, TRVI, EWTX | 13F-HR | 14 Nov 2025, 16:30 |
| Q2 2025 | 44 | $577,150,843 | +$96,766,441 | -$109,400,259 | -$12,633,818 | CGEM, MDGL, ZLAB, GH, SPRY | 13F-HR | 14 Aug 2025, 16:45 |
| Q1 2025 | 43 | $581,677,555 | +$124,132,114 | -$131,904,699 | -$7,772,585 | CGEM, MDGL, ZLAB, EWTX, LNTH | 13F-HR | 15 May 2025, 16:45 |
| Q4 2024 | 47 | $704,362,373 | +$199,450,688 | -$70,469,706 | +$128,980,982 | CGEM, CRNX, EWTX, INSM, NTRA | 13F-HR | 14 Feb 2025, 16:20 |
| Q3 2024 | 43 | $666,570,839 | +$121,902,236 | -$113,688,535 | +$8,213,701 | CGEM, INSM, OLMA, RNA, CRNX | 13F-HR | 12 Nov 2024, 19:40 |
| Q2 2024 | 44 | $643,506,945 | +$157,959,921 | -$64,182,632 | +$93,777,289 | CGEM, INSM, OLMA, ITOS, CRNX | 13F-HR | 14 Aug 2024, 11:32 |
| Q1 2024 | 38 | $621,981,029 | +$161,395,991 | -$77,672,999 | +$83,722,992 | CGEM, GERN, IOVA, ZNTL, ITOS | 13F-HR | 15 May 2024, 16:22 |
| Q4 2023 | 32 | $427,428,816 | +$25,421,555 | -$32,488,966 | -$7,067,411 | CGEM, IOVA, OLMA, GERN, ITOS | 13F-HR | 13 Feb 2024, 16:06 |
| Q3 2023 | 32 | $374,602,543 | +$58,621,803 | -$121,103,281 | -$62,481,478 | CGEM, OLMA, GERN, RPTX, ITOS | 13F-HR | 14 Nov 2023, 16:38 |
| Q2 2023 | 34 | $496,602,631 | +$138,075,141 | -$67,708,606 | +$70,366,535 | CGEM, ISEE, KDNY, GERN, RETA | 13F-HR | 14 Aug 2023, 11:19 |
| Q1 2023 | 31 | $384,916,993 | +$43,120,355 | -$29,195,570 | +$13,924,785 | CGEM, PRVB, ISEE, ITOS, INBX | 13F-HR | 12 May 2023, 13:02 |
| Q4 2022 | 33 | $385,456,912 | +$49,520,591 | -$60,958,042 | -$11,437,451 | CGEM, ITOS, INBX, RPTX, ISEE | 13F-HR | 14 Feb 2023, 12:41 |
| Q3 2022 | 38 | $422,223,000 | +$74,289,940 | -$14,920,995 | +$59,368,945 | CGEM, ITOS, INBX, VERV, NTLA | 13F-HR | 14 Nov 2022, 10:22 |
| Q2 2022 | 37 | $356,826,000 | +$41,243,001 | -$22,144,712 | +$19,098,289 | CGEM, ITOS, RPTX, MRUS, NTLA | 13F-HR | 11 Aug 2022, 17:27 |
| Q1 2022 | 37 | $372,610,000 | +$23,531,324 | -$38,690,490 | -$15,159,166 | CGEM, ITOS, MRUS, RPTX, HARP | 13F-HR | 13 May 2022, 12:05 |
| Q4 2021 | 33 | $548,527,000 | +$39,123,330 | -$58,447,055 | -$19,323,725 | CGEM, ITOS, RPTX, MEIP, MRUS | 13F-HR | 11 Feb 2022, 16:37 |
| Q3 2021 | 33 | $644,676,000 | +$155,338,368 | -$13,196,050 | +$142,142,318 | CGEM, ITOS, RPTX, HOWL, MEI Pharma, Inc. | 13F-HR | 12 Nov 2021, 18:19 |
| Q2 2021 | 14 | $608,714,000 | +$41,647,000 | -$24,965,584 | +$16,681,416 | CGEM, ITOS, TCRR, RPTX, HARP | 13F-HR | 13 Aug 2021, 09:24 |
| Q1 2021 | 13 | $795,909,000 | +$329,772,000 | -$33,653,407 | +$296,118,593 | CGEM, HARP, ITOS, TCRR, RPTX | 13F-HR | 13 May 2021, 15:46 |
| Q4 2020 | 13 | $569,376,000 | +$76,849,000 | -$5,681,882 | +$71,167,118 | TCRR, RPTX, ITOS, ONCR, HARP | 13F-HR/A | 24 Feb 2021, 16:55 |
| Q4 2020 | 16 | $588,506,000 | +$90,297,000 | $0 | +$90,297,000 | TCRR, RPTX, ITOS, ONCR, HARP | 13F-HR | 16 Feb 2021, 06:45 |
| Q3 2020 | 12 | $415,058,000 | +$64,353,810 | $0 | +$64,353,810 | RPTX, TCRR, HARP, ITOS, EPZM | Restatement | 19 Nov 2020, 14:36 |
| Q2 2020 | 11 | $376,116,000 | +$126,680,721 | -$7,727,000 | +$118,953,721 | RPTX, HARP, TCRR, MEI Pharma, Inc., EPZM | 13F-HR | 12 Aug 2020, 12:12 |
| Q1 2020 | 10 | $163,704,000 | +$13,786,000 | -$46,766,000 | -$32,980,000 | HARP, EPZM, TCRR, GTHX, TPTX | 13F-HR | 13 May 2020, 12:16 |
| Q4 2019 | 12 | $282,172,000 | $0 | $0 | $0 | HARP, EPZM, TCRR, GTHX, ARQL | 13F-HR | 14 Feb 2020, 15:03 |